Drugs to reduce liver scarring in chronic hepatitis C

This trial tests whether atorvastatin (a cholesterol medicine) can lower the chance of liver cancer (HCC) in people with advanced liver scarring or cirrhosis. Participants are compared to placebo (inactive pill) while researchers track safety and cancer risk.

This study tests whether taking zinc sulfate can help reduce liver scarring in people with chronic hepatitis B who are already on antiviral medication. If you have moderate liver scarring, you may join to see if zinc improves your liver health.

This Phase 2 trial tests whether rosuvastatin (a cholesterol-lowering medicine) can improve how well the liver functions and slow worsening scarring in people with cirrhosis. It also checks for side effects and safety.

This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.

This trial studies whether simvastatin (a cholesterol medicine) can improve or slow scarring of the liver caused by long-term alcohol use. Participants must have confirmed liver fibrosis on biopsy and be in a stable (compensated) phase of liver disease.

This trial tests a long-term treatment called hydronidone for liver scarring (fibrosis) caused by chronic hepatitis B. It aims to see if the treatment can help slow or reverse liver damage in people who are already on antiviral therapy or starting treatment for the first time.